Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

BACKGROUND: EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Waddell, Tom, Chau, Ian, Cunningham, David, Gonzalez, David, Okines, Alicia Frances Clare, Wotherspoon, Andrew, Saffery, Claire, Middleton, Gary, Wadsley, Jonathan, Ferry, David, Mansoor, Wasat, Crosby, Tom, Coxon, Fareeda, Smith, David, Waters, Justin, Iveson, Timothy, Falk, Stephen, Slater, Sarah, Peckitt, Clare, Barbachano, Yolanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/
https://www.ncbi.nlm.nih.gov/pubmed/23594787
http://dx.doi.org/10.1016/S1470-2045(13)70096-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669518/
https://www.ncbi.nlm.nih.gov/pubmed/23594787
http://dx.doi.org/10.1016/S1470-2045(13)70096-2

Ejemplares similares